Search
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersErtugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 20...
Categories: P-glycoprotein substratesPrulifloxacin
go.drugbank.com/drugs/DB11892InvestigationalPrulifloxacin has been investigated for the treatment of Urinary Tract Infection.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsIlaprazole
go.drugbank.com/drugs/DB11964InvestigationalIlaprazole has been investigated in Helicobacter Infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIberdomide
go.drugbank.com/drugs/DB12101InvestigationalIberdomide is an orally administered cereblon-modulating protein degrader (CELMoD) used to treat multiple myeloma. It binds cereblon, the substrate-recognition component of an E3 ubiquitin ligase complex, and drives the ubiquitination an...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDefactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigationalDefactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. FAK is important for the integrin-...
Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of a...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inh...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSecnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigationalSecnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-l...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: SECNIDAZOL 500 MG POLVO P RECONSTRUIR, SECNIDAZOL 750 MG POLVO P. RECOSTRUIR